CASI Pharmeceuticals

Investor Center

CASI is a biopharmaceutical company focused on the acquisition, development, and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market, with a focus on China and the U.S.

CASI offers the following value drivers:

  • Development of New Chemical Entities – ENMD-2076 for the treatment of multiple solid tumors.
  • Acquisition of Approved Products – Commercialization in greater China, including China, Taiwan, Hong Kong, and Macau.

Market - Well-positioned to pursue significant and unprecedented market opportunities in China and worldwide.

Model - Compelling business model with important North America/China synergies and competitive advantage with efficiency and effectiveness for drug development and commercialization.

Product - A strong and growing product pipeline developed under dual models of acquisition and internal development.

Management - An experienced, motivated leadership team with a track record of accomplishment in both North America and China.

Finance - Strong cash position, backed by successful venture fund and smart money, under careful financial management with low burn rate.

Value Drivers - Significant defined near-term value drivers supporting long-term growth.

Investor Downloads

Corporate Presentation
Partnering Presentation

Annual Stockholders Meeting Notice and Proxy

June 2, 2016
Download proxy & meeting materials

10-K Downloads

2013, 2014, 2015, 2016

Safe Harbor Information

Statements herein that are not descriptions of historical facts are forward-looking and subject to risk and uncertainties. Actual results may differ materially from those currently anticipated due to a number of factors, including those set forth in the Company’s Securities and Exchange Commission filings under “Risk Factors,” including risks relating to our ability to obtain additional financing; the early-stage products under development; uncertainties relating to clinical trials; our success in the further clinical development of ENMD-2076; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company’s proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).

About Us

A leading US-headquartered, NASDAQ-listed, biopharmaceutical company targeting the global market, with a focus on China.

Learn More

In the News

CASI's turnaround turns eastward; firm seeks to be Celgene of China

Read Article →


Clinical Safety and Efficacy of the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated, Locally Advanced or Metastatic Triple-Negative Breast Cancer

Download →


Rodman & Renshaw 19th Annual Global Investment Conference

Download →